Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2018

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

	Three Months Ended				Six Months Ended
(In thousands)	December 31,				December 31,
Medical Indication	2018		2017		2018		2017
Antibiotic	$	4,187	$	3,552	$	8,276	$	6,900
Anti-Psychosis		14,036		22,799		24,924		37,791
Cardiovascular		25,680		10,135		47,450		21,441
Central Nervous System		6,187		6,925		13,384		15,742
Gallstone		2,489		5,282		4,703		11,846
Gastrointestinal		10,009		15,055		25,048		29,608
Glaucoma		512		2,164		1,060		4,832
Migraine		12,551		15,484		22,288		30,499
Muscle Relaxant		3,121		3,219		6,300		7,010
Pain Management		8,968		6,128		13,915		11,889
Respiratory		1,163		2,230		2,178		3,876
Thyroid Deficiency		88,477		68,794		142,354		116,008
Urinary		1,606		2,840		3,158		5,837
Other		6,827		13,105		21,168		25,802
Contract manufacturing revenue		7,905		6,593		12,566		10,185
Net sales	$	193,718	$	184,305	$	348,772	$	339,266

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2018		2017		2018		2017
Product 1	46	%	37	%	41	%	34	%
Product 2	7	%	12	%	7	%	10	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2018		2017		2018		2017
Customer A	18	%	22	%	23	%	25	%
Customer B	14	%	—	%	8	%	—	%
Customer C	14	%	19	%	16	%	20	%
Customer D	13	%	5	%	11	%	5	%
Customer E	3	%	13	%	3	%	8	%